Related Experiment Video
Updated: Jun 2, 2026

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis
Published on: January 26, 2024
The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway
Paola Martinelli1, Paola Bonetti, Cristina Sironi
1Department of Experimental Oncology, European Institute of Oncology, Via Adamello 16, Milan, Italy.
Abstract:
Oncogene-induced senescence (OIS) is a barrier for tumor development. Oncogene-dependent DNA damage and activation of the ARF/p53 pathway play a central role in OIS and, accordingly, ARF and p53 are frequently mutated in human cancer. A number of leukemia/lymphoma-initiating oncogenes, however, inhibit ARF/p53 and only infrequently select for ARF or p53 mutations, suggesting the involvement of other tumor-suppressive pathways. We report that NPM-ALK, the initiating oncogene of anaplastic large cell lymphomas (ALCLs), induces DNA damage and irreversibly arrests the cell cycle of primary fibroblasts and hematopoietic progenitors. This effect is associated with inhibition of p53 and is caused by activation of the p16INK4a/pRb tumor-suppressive pathway. Analysis of NPM-ALK lymphomagenesis in transgenic mice showed p16INK4a-dependent accumulation of senescent cells in premalignant lesions and decreased tumor latency in the absence of p16INK4a. Accordingly, human ALCLs showed no expression of either p16INK4a or pRb. Up-regulation of the histone-demethylase Jmjd3 and de-methylation at the p16INK4a promoter contributed to the effect of NPM-ALK on p16INK4a, which was transcriptionally regulated. These data demonstrate that p16INK4a/pRb may function as an alternative pathway of oncogene-induced senescence, and suggest that the reactivation of p16INK4a expression might be a novel strategy to restore the senescence program in some tumors.
Insights
Oncogene-induced senescence (OIS) acts as a tumor barrier. The p16INK4a/pRb pathway, not ARF/p53, drives OIS in anaplastic large cell lymphomas, offering a new therapeutic target.
Area of Science:
- Oncology
- Cellular Biology
- Molecular Biology
Background:
- Oncogene-induced senescence (OIS) is a crucial tumor suppressor mechanism.
- The ARF/p53 pathway is commonly involved in OIS and frequently mutated in cancer.
- Some oncogenes bypass ARF/p53, implying alternative senescence pathways.
Purpose of the Study:
- To investigate the OIS pathway activated by NPM-ALK, the oncogene in anaplastic large cell lymphomas (ALCLs).
- To determine the role of the p16INK4a/pRb pathway in NPM-ALK-driven lymphomagenesis.
- To explore therapeutic strategies targeting senescence in ALCLs.
Main Methods:
- Induction of OIS by NPM-ALK in primary fibroblasts and hematopoietic progenitors.
- Analysis of cell cycle arrest, DNA damage, and pathway activation (ARF/p53, p16INK4a/pRb).
- Utilized transgenic mouse models of NPM-ALK lymphomagenesis and analyzed human ALCL samples.
- Investigated the epigenetic regulation of p16INK4a expression via Jmjd3.
Main Results:
- NPM-ALK induces cell cycle arrest and DNA damage, inhibiting p53 but activating the p16INK4a/pRb pathway.
- p16INK4a is essential for senescence in premalignant lesions and tumor suppression in NPM-ALK-driven lymphoma.
- Human ALCLs lack p16INK4a and pRb expression, with NPM-ALK upregulating Jmjd3 to suppress p16INK4a transcriptionally.
- Histone demethylase Jmjd3 mediates NPM-ALK-induced silencing of p16INK4a.
Conclusions:
- The p16INK4a/pRb pathway serves as an alternative senescence mechanism to ARF/p53 in response to oncogene activation.
- NPM-ALK oncogene inhibits p53 and activates p16INK4a/pRb pathway, leading to senescence.
- Restoring p16INK4a expression presents a potential therapeutic strategy for ALCLs and other tumors bypassing ARF/p53.
Related Concept Videos
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
